Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...
The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
Elanco Animal Health is making progress on debt repayment, new product approvals, and launches. Learn why ELAN stock is a Buy ...
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...
As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...
Zacks.com on MSN2d
Regeneron Reports Eylea Sales, Provides Other Pipeline UpdatesRegeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback